Pharmaceutical-Bio Industry's First-Quarter 2015 Capital and Maintenance Project Starts Near $4 Billion Investment in North America
Pharmaceutical-Bio Industry's First-Quarter 2015 Capital and Maintenance Project Starts Near $4 Billion Investment in North America
Attachment: Pharmaceutical-Biotech Kickoffs, 1Q15
SUGAR LAND--January 20, 2015--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--As the first quarter of 2015 gathers steam, the Pharmaceutical-Biotech Industry is projected to launch $3.9 billion worth of North American projects through the end of March. A healthy cash injection of that magnitude is cause for jubilation, or at the least, cautious optimism.
Within this article: Details on the industry's North American kickoffs in first-quarter 2015, including major projects from AstraZeneca (NYSE:AZN), Gilead Sciences (NASDAQ:GILD) and the U.S. Army Public Health Command.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- California Gears Up for $3.9 Billion in Third-Quarter Project Completions
- It's a Wrap! Pharma-Biotech Industry Set To Complete 268 North American CAP...
- Pharma-Biotech Capital Construction 2015 Investment Review: $15 Billion in ...
- Uncle Sam Kicks Off Construction of $250 Million Maryland Public Health Com...
- Mid-Atlantic's 10 Top-Value Projects for Next Quarter Show Growing Roles fo...